
Home » Opyl Unveils AI Platform That Predicts Drug, Vaccine Success in Clinical Trials
Opyl Unveils AI Platform That Predicts Drug, Vaccine Success in Clinical Trials
Artificial intelligence (AI) company Opyl has launched a new AI software platform that can predict the success or failure of vaccines or antibody therapies targeting COVID-19 in clinical trials. Opyl’s AI forecasting model has examined 475 registered COVID-19 trials across the globe to help predict the drugs or devices that have the greatest chance of success.
The platform has predicted that the COVID-19 therapies have a much higher chance of approval than do the vaccines being studied and that an antibody therapy has the highest probability of a positive phase 3 outcome over all other therapies being studied.
Related Directories
Upcoming Events
-
05Dec
-
14Apr